How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Remifentanil Hydrochloride for Injection Market
- By Dosage Strength: 1 mg/10 mL, 2 mg/20 mL, 5 mg/50 mL, 10 mg/100 mL
- By End-Use Setting: Hospitals, Ambulatory Surgical Centers, Clinics, Specialty Surgical Centers
- By Application: General Anesthesia, Procedural Sedation, Intensive Care Unit Sedation, Labor and Delivery Analgesia
- By Formulation Type: Single-dose Vials, Multi-dose Vials, Pre-filled Syringes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - 1 mg/10 mL leads By Dosage Strength at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the Remifentanil Hydrochloride for Injection Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Dosage Strength 4
End-Use Setting 4
Application 4
Formulation Type 3
Companies profiled
Mylan N.V. (Viatris)
Fresenius Kabi
Hospira (Pfizer)
B. Braun Melsungen AG
Meda AB (part of Mylan/Viatris)
Sandoz (Novartis)
Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals
Lupin Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals
Pfizer Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Mylan N.V. (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Hospira (Pfizer)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Meda AB (part of Mylan/Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sandoz (Novartis)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Teva Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Amneal Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Lupin Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sun Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Hikma Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Baxter International Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Macleods Pharmaceuticals Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cipla Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,637M by 2033 · 8.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- 1 mg/10 mL51.8
- 2 mg/20 mL18.0
- 5 mg/50 mL13.0
- 10 mg/100 mL17.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$943.9M → $1,713M · 7.7%
Europe$657.9M → $1,249M · 8.3%
Asia Pacific$600.7M → $1,195M · 9.0%
Latin America$371.8M → $676.5M · 7.8%
Middle East and Africa$286.0M → $566.6M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.802026
8.822027
8.832028
8.842029
8.852030
8.872031
8.882032
8.892033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Mylan N.V. (Viatris)19.4
- Fresenius Kabi14.2
- Hospira (Pfizer)9.3
- B. Braun Melsungen AG11.3
- Meda AB (part of Mylan/Viatris)10.3
- Sandoz (Novartis)7.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Dosage Strength19.0%
End-Use Setting25.4%
Application35.0%
Formulation Type20.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.7
- Europe23.1
- Asia Pacific22.1
- Latin America12.5
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Mylan N.V. (Viatris) | 98 | 91 | 86 | 79 | 81 | 76 | 85 |
| Fresenius Kabi | 85 | 77 | 75 | 90 | 69 | 77 | 79 |
| Hospira (Pfizer) | 71 | 80 | 73 | 87 | 77 | 70 | 76 |
| B. Braun Melsungen AG | 72 | 58 | 65 | 79 | 74 | 66 | 69 |
| Meda AB (part of Mylan/Viatris) | 73 | 58 | 51 | 55 | 75 | 67 | 63 |
| Sandoz (Novartis) | 52 | 71 | 56 | 57 | 64 | 57 | 60 |
| Teva Pharmaceutical Industries Ltd. | 53 | 45 | 60 | 46 | 62 | 51 | 53 |
| Amneal Pharmaceuticals | 57 | 37 | 54 | 46 | 39 | 48 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Mylan N.V. (Viatris)
- Fresenius Kabi
- Hospira (Pfizer)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Mylan N.V. (Viatris) | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Fresenius Kabi | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Hospira (Pfizer) | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| B. Braun Melsungen AG | ◐ | − | ◐ | ◐ | − | − |
| Meda AB (part of Mylan/Viatris) | ◐ | − | ◐ | − | ◐ | ✓ |
| Sandoz (Novartis) | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | − | ◐ | ◐ | − | ✓ | − |
| Amneal Pharmaceuticals | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Mylan N.V. (Viatris)85
2Fresenius Kabi79
3Hospira (Pfizer)76
4B. Braun Melsungen AG69
5Meda AB (part of Mylan/Viatris)63
6Sandoz (Novartis)60
7Teva Pharmaceutical Industries Ltd.53
8Amneal Pharmaceuticals47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Mylan N.V. (Viatris)Fresenius Kabi
Challenger2
Strong scale, closing on the leaders.
Hospira (Pfizer)B. Braun Melsungen AG
Contender2
Focused players with pockets of strength.
Meda AB (part of Mylan/Viatris)Sandoz (Novartis)
Niche2
Specialists in a single segment or region.
Teva Pharmaceutical Industries Ltd.Amneal Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Dosage Strength in North America, then scale across Remifentanil Hydrochloride for Injection Market — a $255M beachhead inside a $3.85B market.
Beachhead (SOM)$255Mobtainable near-term
Serviceable (SAM)$1.46Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
1 mg/10 mL
Best fit — highest urgency & budget in Dosage Strength.
Economic buyer79 fit
2 mg/20 mL
Strong fit — clear ROI and a fast path to value.
End user65 fit
5 mg/50 mL
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Dosage Strength in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End-Use Setting & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve20%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Dosage Strength leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Remifentanil Hydrochloride for Injection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation14%
Closed-won6%
$17.0KCAC
$65KLTV
3.8:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Remifentanil Hydrochloride for Injection Market is a high-growth opportunity — $6.88B by 2033, compounding at 10.8%.
TAM · 2025$3.03Btoday
TAM · 2033$6.88Bforecast
CAGR10.8%2027–2033
Cumulative$42.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.88BTotal addressable market
SAM$2.40BServiceable available market
SOM$458MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.8% CAGR
Demand compounds through 2033, outpacing GDP across Dosage Strength.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Dosage Strength moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.88BLarge & growingTAM by 2033 at 10.8% CAGR
$2.40BServiceable nowreachable with today’s model
$458MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.36BBear7.0% CAGR
$6.88BBase10.8% CAGR
$8.80BBull14.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End-Use Setting optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Remifentanil Hydrochloride for Injection Market — a $6.19B market by 2033. Plan: grow share from 6.8% to 13.8%.
Market size · 2033$6.19Btotal addressable
Market CAGR6.8%2027–2033
Target share13.8%from 6.8% today
Revenue ambition$854Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 13.8% | On track |
| Revenue | $386M | $854M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.5% | 43.5% | Ahead |
| Customer retention | 90.4% | 92.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Dosage Strength
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End-Use Setting capability
A defensible second engine — invest in End-Use Setting to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Dosage Strength share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End-Use Setting
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $94M capacity & capability investment
- Greenlight bolt-on M&A in End-Use Setting
- Authorise North America expansion plan
- Fund R&D program for Dosage Strength leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Remifentanil Hydrochloride for Injection Market conversation — a $3.63B market you can size, segment and defend in minutes.
Market size · 2033$3.63Btotal opportunity
Growth4.4%CAGR to 2033
Addressable buyers1,023+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Dosage Strength
Goal Grow share in Dosage Strength
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 3 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Mylan N.V. (Viatris)Fresenius KabiHospira (Pfizer)B. Braun Melsungen AGMeda AB (part of Mylan/Viatris)Sandoz (Novartis)Teva Pharmaceutical Industries Ltd.Amneal Pharmaceuticals+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Remifentanil Hydrochloride for Injection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Remifentanil Hydrochloride for Injection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Remicade (Infliximab) Monoclonal Antibody Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportRemicade (Infliximab) and Biosimilar Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportRemdesivir (COVID-19) Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportRemdesivir API Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportRelugolix API Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportReloadable Linear Stapler Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportRelaxation and Meditation App Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportRelative Analgesia Machine Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportRelationship Counselling Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportRelapsing-Remitting Multiple Sclerosis Market
Market size, share, segmentation and regional forecast.
$611M market · 2025 base year
View reportRelapsing Multiple Sclerosis Treatment Market
Market size, share, segmentation and regional forecast.
$441M market · 2025 base year
View reportRehabilitation Wall Bars Market
Market size, share, segmentation and regional forecast.
$420M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.